8
858 Therapeutics
Biotechnology firm developing small molecule drugs targeting oncology, neuroscience, and cardiovascular diseases
About 858 Therapeutics
858 Therapeutics is a biotechnology startup based in San Diego, California, specializing in the development of innovative small molecule drugs. These drugs are designed to target novel therapeutic areas in oncology and neuroscience. The company's primary focus is on the emerging fields of synthetic lethality, innate immunity, and RNA modulation. In simpler terms, they are developing drugs that can target and kill cancer cells, boost the body's natural defenses, and manipulate RNA, a molecule that plays a crucial role in the coding, decoding, regulation, and expression of genes.
The company's lead program is directed at PARG, a new target in the DNA damage repair pathway. This pathway is a system within the cell that identifies and corrects damage to the DNA molecule that encodes its genetic information. The company plans to begin a phase 1 trial for this program in 2024.
858 Therapeutics serves a market that includes patients suffering from cancers resistant to current therapies. Their business model is centered around the research, development, and eventual commercialization of their small molecule drugs. The company generates revenue through the successful development and sale of these drugs.
The startup was founded by a team of industry veterans with a proven track record in pharmaceutical and biotech drug discovery. The team's collective experience in oncology and drug development is a key asset in their mission to discover innovative therapeutics.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Diego, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 61.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Genetics and genomics, Biotech and Pharma, mRNA Medicines, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2024 | $50M | $300M | NEA · Mirae Asset Capital · Insight Partners · Versant Ventures | ↗ |
| SERIES AOther financing | Sep 2021 | $60M | $240M | Cormorant Asset Management · Logos Capital · Versant Ventures · NEA | — |
Growth signals
Latest recorded traffic for 858 Therapeutics is 3.4K monthly website visits, up 142.9% over the last three months. 858 Therapeutics's team declined 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Versant Ventures
Cormorant Asset Management
Logos Capital
NEA
Avidity Partners
Mirae Asset Capital
Insight Partners
Alexandria Venture Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about 858 Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See 858 Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.